Genetics of nervous system tumors

Hematology/Oncology Clinics of North America

Volumn 15, Issue 6, 2001, Pages 961-978

  Shapiro, Joan Rankin ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE;

ASTROCYTOMA; CANCER GENETICS; CELL CYCLE; DISEASE ASSOCIATION; GENE MUTATION; GLIOBLASTOMA; HUMAN; NERVOUS SYSTEM TUMOR; OLIGODENDROGLIOMA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0035204877     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70262-8     Document Type: Article

References (78)

1. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors
2. Allelic status of chromosome 1 in neoplasms of the nervous system
3. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
4. Patterns of the early, gross chromosomal changes in malignant human gliomas
5. Molecular analysis of genetic changes in ependymomas
6. Growth factors in brain tumors
7. Brain tumors
8. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
9. Astrocytic tumours
10. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma
11. Genes and chromosomal alterations associated with the development of human gliomas
12. TP53 tumor suppressor gene: A model for investigating human mutagenesis
13. Platelet-derived growth factor and its receptor expression in human oligodendrogliomas
14. Molecular genetic analysis of ependymal tumors: NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas
15. Amplified and rearranged EGFR genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails
16. DCC gene mutations and loss of expression in glioblastomas
17. Deletion mapping of the long arm of chromosome 10 in glioblastoma multiforme
18. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25qter
19. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop
20. Platelet derived growth factor (PDGF) autocrine components in human tumor cell lines
21. INK4 or retinoblastoma protein pRb., or amplification-associated overexpression of cdk 4 is observed in distinct subsets of malignant glial tumors and cell lines
22. Endothelial cell hyperplasia in human glioblastoma: Coexpression of mRNA for platelet-derived growth factor PDGF B chain and PDGF receptor suggests autocrine growth stimulation
23. Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops
24. Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups
25. Analysis of the NF2 tumor-suppressor gene and of chromosome 22 deletions in gliomas
26. Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors
27. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome lp loss
28. Molecular subtypes of anaplastic oligodendroglioma
29. Clonal genomic alterations in glioma malignancy stages
30. PTEN mutation analysis in two genetic subtypes of high-grade oligodendroglial tumors: PTEN is only occasionally mutated in one of the two genetic subtypes
31. Platelet-derived growth factor in human brain tumors
32. Primary and secondary glioblastoma: From concept to clinical diagnosis
33. Shared allelic losses on chromosomes lp and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma
34. Expression of p53 in oligodendrogliomas
35. Molecular genetic alterations on chromosomes 11 and 22 in ependymomas
36. Pathways leading to glioblastoma multiforme: A molecular analysis of genetic alterations in 65 astrocytic tumors
37. PTEN a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer
38. p27kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers
39. Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1p-arm deletions
40. Molecular genetic evidence for subtypes of oligoastrocytomas
41. Report of the third international workshop on human chromosome 19 mapping 1996
42. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours
43. Loss of heterozygosity on chromosome 19 in secondary glioblastomas
44. Differential expression of plateletderived growth factor receptors in human malignant glioma cell lines
45. p53 mutations in nonastrocytic human brain tumors
46. Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system
47. Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas
48. Homozygous deletions of the CDKN2C/p18INK4C gene on the short arm of chromosome 1 in anaplastic oligodendrogliomas
49. Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas and oligodendrogliomas
50. Oligodendroglial tumors
51. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations
52. Epidermal growth factor receptor expression in oligodendroglial tumours
53. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p
54. Molecular genetics of oligodendroglial tumors
55. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression
56. Loss of DCC expression and glioma progression
57. Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas
58. Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumours
59. Expression of the tumor suppressor gene DCC in human gliomas
60. BCNU-resistant human glioma cells with over-representation of chromosomes 7 and 22 demonstrate increased copy number and expression of platelet-derived growth factor genes
61. Low frequency of chromosomal imbalances in anaplastic ependymomas as detected by comparative genomic hybridization
62. Central nervous system
63. Brain tumors
64. Alterations of chromosome arms lp and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas
65. Amplification of the platelet-derived growth factor receptor-A PDGFRA gene occurs in oligodendrogliomas with grade IV anaplastic features
66. Molecular analysis of two putative tumour suppressor genes, PTEN and DMBT, which have been implicated in glioblastoma multiforme disease progression
67. Identification of a candidate tumour suppressor gene, MMAC 1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
68. Amplification and overexpression of mdm 2 gene in ependymoma
69. The autocrine loop of TGF-a/EGFR and brain tumors
70. PTEN mutations are frequent in primary glioblastomas de novo, but not in secondary glioblastomas
71. Anaplastic ependymomas: Clinical features and tumour suppressor gene p53 analysis
72. Vascular endothelial growth factor expression in oligodendrogliomas: A correlative study with Stainte-Anne malignancy grade, growth fraction and patient survival
73. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytomas
74. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas
75. Subsets of glioblastomas multiforme defined by molecular genetic analysis
76. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies
77. Chromosome 19q deletions in humangliomas overlap telomeric to D19S219 and may target a 425 kb region centromeric to D19S112